Skip to main content
Erschienen in: Irish Journal of Medical Science (1971 -) 3/2008

01.09.2008 | Original Article

Diagnosis of new onset heart failure in the community: the importance of a shared-care approach and judicious use of BNP

verfasst von: G. Mak, M. Ryder, N. F. Murphy, C. O’Loughlin, D. McCaffrey, M. Ledwidge, K. McDonald

Erschienen in: Irish Journal of Medical Science (1971 -) | Ausgabe 3/2008

Einloggen, um Zugang zu erhalten

Abstract

Background

Brain natriuretic peptide (BNP) may help general practitioners (GPs) to “rule-out” heart failure (HF) and reduce referral burden on specialist assessment clinics.

Aims

To determine the diagnostic value of BNP in HF referrals by GPs to a specialist unit.

Methods

From 2003 to 2007, 327 GP referrals were made to a HF new patient diagnostic clinic (NDC) with a provisional diagnosis of HF. The NDC provides rapid assessment of potential HF patients and ensures appropriate therapy and follow-up for those with a confirmed diagnosis. HF diagnosis was confirmed by the Framingham criteria.

Results

HF was present in 39% of cases referred (mean age 75 ± 10 years, 49% male). The inclusion of BNP as a “rule-out” test with a cut-off value of 100 pg/mL would have reduced the number of patients originally referred to the NDC by 175. However, this would have resulted in delayed diagnosis and treatment of 20 (16%) “false-negative” patients.

Conclusions

Availability of BNP to GPs would improve referral patterns but with high risk of delayed diagnosis. The data underline the need for a shared-care approach to the new diagnosis of HF.
Literatur
2.
Zurück zum Zitat Khunti K, Hearnshaw H, Baker R, Grimshaw G (2002) Heart failure in primary care: qualitative study of current management and perceived obstacles to evidence-based diagnosis and management by general practitioners. Eur J Heart Fail 4(6):771–777. doi:10.1016/S1388-9842(02)00119-8 PubMedCrossRef Khunti K, Hearnshaw H, Baker R, Grimshaw G (2002) Heart failure in primary care: qualitative study of current management and perceived obstacles to evidence-based diagnosis and management by general practitioners. Eur J Heart Fail 4(6):771–777. doi:10.​1016/​S1388-9842(02)00119-8 PubMedCrossRef
4.
Zurück zum Zitat Zaphiriou A, Robb S, Murray-Thomas T et al (2005) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7(4):537–541. doi:10.1016/j.ejheart.2005.01.022 PubMedCrossRef Zaphiriou A, Robb S, Murray-Thomas T et al (2005) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7(4):537–541. doi:10.​1016/​j.​ejheart.​2005.​01.​022 PubMedCrossRef
5.
Zurück zum Zitat Fox KF, Cowie MR, Wood DA, Coats AJ, Poole-Wilson PA, Sutton GC (2000) A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. Eur J Heart Fail 2(4):423–429. doi:10.1016/S1388-9842(00)00108-2 PubMedCrossRef Fox KF, Cowie MR, Wood DA, Coats AJ, Poole-Wilson PA, Sutton GC (2000) A Rapid Access Heart Failure Clinic provides a prompt diagnosis and appropriate management of new heart failure presenting in the community. Eur J Heart Fail 2(4):423–429. doi:10.​1016/​S1388-9842(00)00108-2 PubMedCrossRef
8.
Zurück zum Zitat Fuat A, Murphy JJ, Hungin AP et al (2006) The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 56(526):327–333PubMed Fuat A, Murphy JJ, Hungin AP et al (2006) The diagnostic accuracy and utility of a B-type natriuretic peptide test in a community population of patients with suspected heart failure. Br J Gen Pract 56(526):327–333PubMed
10.
Zurück zum Zitat Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22(4 Suppl A):6A–13APubMedCrossRef Ho KK, Pinsky JL, Kannel WB, Levy D (1993) The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 22(4 Suppl A):6A–13APubMedCrossRef
11.
Zurück zum Zitat The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327(10):685–691 The SOLVD Investigators (1992) Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327(10):685–691
13.
Zurück zum Zitat Mueller C, Frana B, Rodriguez D, Laule-Kilian K, Perruchoud AP (2005) Emergency diagnosis of congestive heart failure: impact of signs and symptoms. Can J Cardiol 21(11):921–924PubMed Mueller C, Frana B, Rodriguez D, Laule-Kilian K, Perruchoud AP (2005) Emergency diagnosis of congestive heart failure: impact of signs and symptoms. Can J Cardiol 21(11):921–924PubMed
15.
Zurück zum Zitat Remes J, Miettinen H, Reunanen A, Pyorala K (1991) Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 12(3):315–321PubMed Remes J, Miettinen H, Reunanen A, Pyorala K (1991) Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 12(3):315–321PubMed
16.
Zurück zum Zitat Sim V, Hampton D, Phillips C et al (2003) The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction-cost-effectiveness in relation to open access echocardiography. Fam Pract 20(5):570–574. doi:10.1093/fampra/cmg513 PubMedCrossRef Sim V, Hampton D, Phillips C et al (2003) The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction-cost-effectiveness in relation to open access echocardiography. Fam Pract 20(5):570–574. doi:10.​1093/​fampra/​cmg513 PubMedCrossRef
17.
Zurück zum Zitat Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG (2004) Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43(6):1019–1026. doi:10.1016/j.jacc.2003.10.043 PubMedCrossRef Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG (2004) Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43(6):1019–1026. doi:10.​1016/​j.​jacc.​2003.​10.​043 PubMedCrossRef
18.
Zurück zum Zitat Nielsen OW, McDonagh TA, Robb SD, Dargie HJ (2003) Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 41(1):113–120. doi:10.1016/S0735-1097(02)02625-6 PubMedCrossRef Nielsen OW, McDonagh TA, Robb SD, Dargie HJ (2003) Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 41(1):113–120. doi:10.​1016/​S0735-1097(02)02625-6 PubMedCrossRef
19.
Zurück zum Zitat Steg PG, Joubin L, McCord J et al (2005) B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 128(1):21–29. doi:10.1378/chest.128.1.21 PubMedCrossRef Steg PG, Joubin L, McCord J et al (2005) B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 128(1):21–29. doi:10.​1378/​chest.​128.​1.​21 PubMedCrossRef
20.
Zurück zum Zitat Steg PG, Joubin L, McCord J et al (2005) B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 128(1):21–29. doi:10.1378/chest.128.1.21 PubMedCrossRef Steg PG, Joubin L, McCord J et al (2005) B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 128(1):21–29. doi:10.​1378/​chest.​128.​1.​21 PubMedCrossRef
21.
Zurück zum Zitat Francis CM, Caruana L, Kearney P et al (1995) Open access echocardiography in management of heart failure in the community. BMJ 310(6980):634–636PubMed Francis CM, Caruana L, Kearney P et al (1995) Open access echocardiography in management of heart failure in the community. BMJ 310(6980):634–636PubMed
23.
Zurück zum Zitat Murphy JJ, Frain JP, Ramesh P, Siddiqui RN, Bossingham CM (1996) Open-access echocardiography to general practitioners for suspected heart failure. Br J Gen Pract 46(409):475–476PubMed Murphy JJ, Frain JP, Ramesh P, Siddiqui RN, Bossingham CM (1996) Open-access echocardiography to general practitioners for suspected heart failure. Br J Gen Pract 46(409):475–476PubMed
24.
Zurück zum Zitat Fung JW, Yu CM, Yip G et al (2003) Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92(4):406–410. doi:10.1016/S0002-9149(03)00658-1 PubMedCrossRef Fung JW, Yu CM, Yip G et al (2003) Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92(4):406–410. doi:10.​1016/​S0002-9149(03)00658-1 PubMedCrossRef
25.
26.
Zurück zum Zitat Murdoch DR, McDonagh TA, Byrne J et al (1999) Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138(6Pt 1):1126–1132. doi:10.1016/S0002-8703(99)70079-7 PubMedCrossRef Murdoch DR, McDonagh TA, Byrne J et al (1999) Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138(6Pt 1):1126–1132. doi:10.​1016/​S0002-8703(99)70079-7 PubMedCrossRef
28.
Zurück zum Zitat Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR et al (2007) Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 167(4):400–407. doi:10.1001/archinte.167.4.400 PubMedCrossRef Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR et al (2007) Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 167(4):400–407. doi:10.​1001/​archinte.​167.​4.​400 PubMedCrossRef
29.
Zurück zum Zitat Daniels LB, Clopton P, Bhalla V et al (2006) How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly multinational study. Am Heart J 151(5):999–1005. doi:10.1016/j.ahj.2005.10.011 PubMedCrossRef Daniels LB, Clopton P, Bhalla V et al (2006) How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly multinational study. Am Heart J 151(5):999–1005. doi:10.​1016/​j.​ahj.​2005.​10.​011 PubMedCrossRef
31.
Zurück zum Zitat Krauser DG, Lloyd-Jones DM, Chae CU et al (2005) Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dyspnea in the Emergency department (PRIDE) substudy. Am Heart J 149(4):744–750. doi:10.1016/j.ahj.2004.07.010 PubMedCrossRef Krauser DG, Lloyd-Jones DM, Chae CU et al (2005) Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dyspnea in the Emergency department (PRIDE) substudy. Am Heart J 149(4):744–750. doi:10.​1016/​j.​ahj.​2004.​07.​010 PubMedCrossRef
32.
Zurück zum Zitat Maisel AS, McCord J, Nowak RM et al (2003) Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly multinational study. J Am Coll Cardiol 41(11):2010–2017. doi:10.1016/S0735-1097(03)00405-4 PubMedCrossRef Maisel AS, McCord J, Nowak RM et al (2003) Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly multinational study. J Am Coll Cardiol 41(11):2010–2017. doi:10.​1016/​S0735-1097(03)00405-4 PubMedCrossRef
34.
Zurück zum Zitat Zaphiriou A, Robb S, Murray-Thomas T et al (2005) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7(4):537–541. doi:10.1016/j.ejheart.2005.01.022 PubMedCrossRef Zaphiriou A, Robb S, Murray-Thomas T et al (2005) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7(4):537–541. doi:10.​1016/​j.​ejheart.​2005.​01.​022 PubMedCrossRef
36.
Zurück zum Zitat Steg PG, Joubin L, McCord J et al (2005) B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 128(1):21–29. doi:10.1378/chest.128.1.21 PubMedCrossRef Steg PG, Joubin L, McCord J et al (2005) B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 128(1):21–29. doi:10.​1378/​chest.​128.​1.​21 PubMedCrossRef
Metadaten
Titel
Diagnosis of new onset heart failure in the community: the importance of a shared-care approach and judicious use of BNP
verfasst von
G. Mak
M. Ryder
N. F. Murphy
C. O’Loughlin
D. McCaffrey
M. Ledwidge
K. McDonald
Publikationsdatum
01.09.2008
Verlag
Springer-Verlag
Erschienen in
Irish Journal of Medical Science (1971 -) / Ausgabe 3/2008
Print ISSN: 0021-1265
Elektronische ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-008-0186-3

Weitere Artikel der Ausgabe 3/2008

Irish Journal of Medical Science (1971 -) 3/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.